Ascentage Pharma Group International (HKG:6855)
Market Cap | 15.56B |
Revenue (ttm) | 1.04B |
Net Income (ttm) | -431.45M |
Shares Out | 342.64M |
EPS (ttm) | -1.43 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,986,611 |
Average Volume | 3,668,049 |
Open | 45.10 |
Previous Close | 45.90 |
Day's Range | 43.80 - 46.90 |
52-Week Range | 15.42 - 48.85 |
Beta | 1.05 |
RSI | 66.41 |
Earnings Date | Mar 26, 2025 |
About HKG:6855
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]
Financial Performance
In 2024, HKG:6855's revenue was 980.65 million, an increase of 341.77% compared to the previous year's 221.98 million. Losses were -405.43 million, -56.20% less than in 2023.
Financial numbers in CNY Financial StatementsNews

Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
JPMorgan initiated coverage on Ascentage Pharma Group (NASDAQ: AAPG), a commercial-stage Chinese biotech company focusing on cancer treatment . In January, Ascentage Pharma’s American depositary shar...

Earnings Scheduled For March 27, 2025
Companies Reporting Before The Bell • Tsakos Energy Navigation (NYSE: TEN) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. • Worksport (NASDAQ: WKSP) is p...
Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025
Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025

Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American d...

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO
China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China , Dec. 26, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China , Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to addr...

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
ROCKVILLE, Md. and SUZHOU, China , Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to addr...

ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to addr...

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
ROCKVILLE, Md. and SUZHOU, China , Sept.

ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China , Sept.

Ascentage Pharma Announces 2024 Interim Results
ROCKVILLE, Md. and SUZHOU, China , Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-cla...

Ascentage Pharma Received US$100 Million Option Payment from Takeda
ROCKVILLE, Md. and SUZHOU, China, July 3, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class...

Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
ROCKVILLE, Md. and SUZHOU, China , June 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK) announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securi...

Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
ROCKVILLE, Md. and SUZHOU, China , June 20, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR
SUZHOU, China and ROCKVILLE, Md. , June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. Ascentage Pharma to receive an option payment of 100 mill...

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM
SUZHOU, China, and ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
SUZHOU, China and ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CH...

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
SUZHOU, China, and ROCKVILLE, Md. , June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (C...

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB...